MedMira Enters Strategic Partnership with Triplex International Biosciences to Accelerate Growth in China

    HALIFAX, June 30 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ:   MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, announced today that it is making progress on market development in
China through the creation of a strategic partnership with Triplex
International Biosciences Co., Ltd. (Triplex), a major player in China's
diagnostics sector.
    With recorded sales revenue of nearly USD $30 million last year, Triplex
has a well established healthcare customer base, which includes over 2,000
hospitals and medical institutions across 29 provinces and autonomous regions
within China. The Triplex product line is comprised of over 45 molecular
pathology diagnostics products, including some of the top brands in the
industry. Triplex also has access to many experts, academics and doctors
working in hospitals and research institutions across China through the
Chinese Committee of Pathology.
    "This partnership brings the strong sales and marketing platform that
Triplex has built in China together with MedMira's world-class products, to
offer customers quality diagnostic solutions and increase revenue potential
for both companies," said Hermes Chan, CEO of MedMira Inc. "For us China is a
long-term business initiative and working with Triplex is a natural extension
of MedMira's growth strategy for the China market."
    MedMira will initially be working with Triplex to increase product sales
in China through their existing distribution channels. Over the course of the
last few months, Triplex has undertaken market testing with MedMira rapid
tests and the feedback has been very positive. In addition to these pre-sales
customer trials, Triplex also engaged the China Centers for Disease Control
and Prevention (CDC) to evaluate the MedMira tests.
    Chan continued, "We believe our partnership with Triplex will evolve to
include co-development of new rapid tests, technology transfers, and
collaborative research projects in the future. Market conditions are changing
rapidly in the China as new healthcare system reforms take shape. Together
MedMira and Triplex can capitalize on the need for improved and cost-effective
    In April 2009, China's government announced a $125 billion USD investment
in significant reforms to their country's healthcare system. Major initiatives
include the establishment of basic medical services for all urban and rural
residents, universal access to public health services, a basic medical and
drug plan for all residents, and the reorganization of the public hospital
    "We are pleased to work with MedMira in expanding their access to the
China market and offer our customers new rapid diagnostic solutions. The
diagnostics sector and overall healthcare market here in China is rapidly
changing and together Triplex and MedMira can respond to market demand for
better, faster diagnostics," said Yiu Ming Fung, President and Chairman of
Triplex. "Our long-term growth strategies are in line with MedMira's and our
partnership enables the flexibility to develop and commercialize new rapid
tests to meet market demand."
    In addition to sales and distribution of diagnostic products, Triplex
intends to operate independent diagnostic centres to provide fast and
convenient medical testing services. Triplex has identified a number of cities
and regions to set up its diagnostic centers where they will serve the
community directly using Triplex's wide range of diagnostic products and
technical expertise.

    About Triplex International Biosciences Co., Ltd.

    Triplex is one of the leading molecular pathology diagnostic companies in
China and its line of diagnostic solutions is one of the tope brands in the
industry. Over the past five years, Triplex has grown from seven people to a
team of 170 supporting the Company's annual sales growth rate of 400 percent.
Triplex sells more than 45 products to over 2000 hospitals and medical
institutions across 29 provinces and cities in China. The Company has also
developed more than 30 diagnostic products through its Engineering Laboratory
for Molecular Diagnostic Technology in Fuzhou, three R&D centers, and five
joint R&D bases with Peking University Medical School, the Fourth Military
Medical University in Xi-an, Sichuan University, Fujian Medical University, as
well as CAS Shanghai Life Sciences Research Institute. To learn more about
Triplex visit

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E

For further information:

For further information: Andrea Young, MedMira, (902) 450-1588,

Organization Profile

MedMira Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890